NCT00201669View on ClinicalTrials.gov

A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

May 31, 2006

Study Completion Date

June 30, 2006

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Clofarabine

Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.

Trial Locations (1)

43210

Ohio State University, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00201669 - A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter